Enrique G. B.
- Country
- Spain
- Department
- Oncology
Research Overview
- A Phase 2 clinical trial of Pembrolizumab in combination with Carboplatin and Cabazitaxel in Aggressive Variant Metastatic Castration Resistant Prostate Cancer
- Phase 1/2 Evaluation of EPI-7386 and Enzalutamide Combination Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer
- Evaluation of Pembrolizumab-Based Combination Therapies in Metastatic Castration-Resistant Prostate Cancer: A Phase Ib/II Clinical Trial
Data & Insights
Has run more than one trial at 67 of 208 partner sites.
Specializations
Thoracic and Upper Aerodigestive Tract Oncology
Clinical activity in Medical Oncology includes a strong focus on non-small cell lung cancer, small cell lung cancer, and other advanced thoracic malignancies, with additional involvement in head and neck squamous cell carcinoma, esophageal cancer, and mesothelioma.
- Non-small cell lung cancer
- Small cell lung cancer
- Head and neck squamous cell carcinoma
- Mesothelioma
Research interest extends to biomarker-defined and locally advanced or metastatic disease settings, supporting therapeutic innovation in lung and head and neck cancer care.
Breast, Gynecologic, and Genitourinary Malignancies
The investigator is actively involved in studies of breast cancer, including HER2-positive breast cancer, hormone receptor-positive breast cancer, and triple-negative breast cancer, alongside ovarian cancer, endometrial cancer, cervical cancer, urothelial carcinoma, and renal cell carcinoma.
- Breast cancer
- Ovarian cancer
- Endometrial cancer
- Urothelial carcinoma
Work in these domains reflects a sustained therapeutic interest in advanced solid tumors across breast, gynecologic, and urinary tract oncology.
Hematologic Malignancies and Cellular Therapy
Research involvement includes acute myeloid leukemia, multiple myeloma, chronic lymphocytic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, and myelodysplastic syndrome.
- Acute myeloid leukemia
- Multiple myeloma
- Diffuse large B-cell lymphoma
- Myelodysplastic syndrome
The portfolio also includes graft-versus-host disease and other transplant-related hematology topics, indicating engagement with advanced blood cancer therapeutics and immune-based treatment strategies.
Targeted and Biomarker-Driven Solid Tumor Therapy
The investigator participates in trials centered on targeted therapy for advanced solid tumors, including tumors with EGFR, ALK, ROS1, RET, KRAS, HER2, FGFR, and IDH alterations, as well as colorectal cancer, gastric cancer, pancreatic cancer, and hepatocellular carcinoma.
- Biomarker-driven solid tumors
- Colorectal cancer
- Pancreatic cancer
- Hepatocellular carcinoma
This area highlights therapeutic interest in precision oncology and molecularly selected treatment approaches across multiple tumor types.
Myeloid, Plasma Cell, and Rare Hematologic Disorders
Additional clinical research spans myelofibrosis, essential thrombocythemia, polycythemia vera, plasma cell leukemia, light chain amyloidosis, and high-risk smoldering multiple myeloma.
- Myelofibrosis
- Essential thrombocythemia
- Plasma cell leukemia
- Light chain amyloidosis
These studies extend the therapeutic profile into rare and difficult-to-treat hematologic conditions where innovation in disease control remains a major clinical need.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.